Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip).

Chaudhary S, Madhukrishna B, Adhya AK, Keshari S, Mishra SK.

Oncogenesis. 2016 Apr 18;5:e219. doi: 10.1038/oncsis.2016.12.

2.

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

Finn RS, Aleshin A, Slamon DJ.

Breast Cancer Res. 2016 Feb 9;18(1):17. doi: 10.1186/s13058-015-0661-5.

3.

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F.

Clin Cancer Res. 2016 Feb 15;22(4):935-47. doi: 10.1158/1078-0432.CCR-15-0534. Epub 2015 Oct 19.

PMID:
26482043
4.

The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway.

Jia T, Zhang L, Duan Y, Zhang M, Wang G, Zhang J, Zhao Z.

Cancer Cell Int. 2014 Nov 30;14(1):126. doi: 10.1186/s12935-014-0126-4. eCollection 2014.

5.

The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation.

Zhu J, Zhao C, Kharman-Biz A, Zhuang T, Jonsson P, Liang N, Williams C, Lin CY, Qiao Y, Zendehdel K, Strömblad S, Treuter E, Dahlman-Wright K.

Oncogene. 2014 Aug 21;33(34):4340-51. doi: 10.1038/onc.2013.573. Epub 2014 Jan 20.

6.

Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE.

J Clin Invest. 2014 Jan;124(1):156-68. doi: 10.1172/JCI70259. Epub 2013 Dec 9.

7.

MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas.

Mukherjee M, Ge G, Zhang N, Edwards DG, Sumazin P, Sharan SK, Rao PH, Medina D, Pati D.

Oncogene. 2014 Nov 27;33(48):5511-22. doi: 10.1038/onc.2013.493. Epub 2013 Nov 25.

8.

Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Saldanha SN, Tollefsbol TO.

J Cell Physiol. 2014 Apr;229(4):393-406. doi: 10.1002/jcp.24466. Review.

9.

Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.

Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M, Shen K.

PLoS One. 2013 Aug 26;8(8):e72053. doi: 10.1371/journal.pone.0072053. eCollection 2013.

10.

O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.

Kanwal S, Fardini Y, Pagesy P, N'tumba-Byn T, Pierre-Eugène C, Masson E, Hampe C, Issad T.

PLoS One. 2013 Jul 11;8(7):e69150. doi: 10.1371/journal.pone.0069150. Print 2013.

11.

Lapatinib induces p27(Kip1)-dependent G₁ arrest through both transcriptional and post-translational mechanisms.

Tang L, Wang Y, Strom A, Gustafsson JÅ, Guan X.

Cell Cycle. 2013 Aug 15;12(16):2665-74. doi: 10.4161/cc.25728. Epub 2013 Jul 29.

12.

New insights on the role of hormonal therapy in ovarian cancer.

Simpkins F, Garcia-Soto A, Slingerland J.

Steroids. 2013 Jun;78(6):530-7. doi: 10.1016/j.steroids.2013.01.008. Epub 2013 Feb 8. Review.

13.

Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.

Hoffman KL, Lerner SP, Smith CL.

Horm Cancer. 2013 Feb;4(1):24-35. doi: 10.1007/s12672-012-0123-9. Epub 2012 Sep 11.

14.

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.

Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15.

15.

Androgen receptor as a targeted therapy for breast cancer.

Garay JP, Park BH.

Am J Cancer Res. 2012;2(4):434-45. Epub 2012 Jun 28.

16.

An essential role of p27 downregulation in fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.

Gao X, Yu L, Castro L, Tucker CJ, Moore AB, Xiao H, Dixon D.

Am J Physiol Endocrinol Metab. 2012 Oct 15;303(8):E1025-35. doi: 10.1152/ajpendo.00107.2012. Epub 2012 Jul 31.

17.

Regulation of chemoresistance via alternative messenger RNA splicing.

Eblen ST.

Biochem Pharmacol. 2012 Apr 15;83(8):1063-72. doi: 10.1016/j.bcp.2011.12.041. Epub 2012 Jan 8. Review.

18.

Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma.

Mirchandani D, Roses DF, Inghirami G, Zeleniuch-Jacquotte A, Cangiarella J, Guth A, Safyan RA, Formenti SC, Pagano M, Muggia F.

Anticancer Res. 2011 Dec;31(12):4401-5.

19.

Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.

Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP.

Cancer Biol Ther. 2011 Nov 15;12(10):924-38. doi: 10.4161/cbt.12.10.17780. Epub 2011 Nov 15.

20.

Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK.

Breast Cancer Res. 2011 Aug 11;13(3):R80. doi: 10.1186/bcr2929.

Items per page

Supplemental Content

Write to the Help Desk